United States Patent 7,863,288 (US7863288): scope, claim coverage, and downstream patent landscape for Formula III compounds and compositions
Executive summary
US7863288 claims a broad genus of Formula III compounds defined by variable substituents at R81, R83, R112, and R68 with strict structural “linkage” exclusions for heteroatom/unsaturation adjacency. Claim coverage expands into compositions (carrier + compound) and kits, and then narrows through many dependent claims that recite specific concrete sulfonamide/sulfonate-bearing pyrrolo[2,3-b]pyridine–benzamide/acid derivatives (including numerous benzene-, benzo[b]thiophene-, and heteroaryl-sulfonamide examples).
The practical enforceable scope is driven by (1) how wide the Formula III genus is allowed to read under claim construction (especially the R68/R81/R112 substitution rules), and (2) whether later patents or continuation filings in the same family add narrower claims on the specific marketed embodiments and their salts, polymorphs, prodrugs, formulations, and method-of-use. Those follow-on layers typically determine infringement risk more than the high-level genus claim alone.
What patents protect Formula III compounds like US7863288 and their sulfonamide/salt embodiments?
Core protection: US7863288’s independent claim 1 protects any compound matching Formula III structural requirements, plus pharmaceutically acceptable salts, where the allowed substituent sets and the linkage constraints are satisfied.
What structural constraints control whether a product falls inside the claim?
Claim 1 is a genus defined by Formula III with four key variable groups:
- R81: broad functional/fragment list (H, halogen, substituted lower alkyl/alkenyl/alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and multiple heteroatom-containing substituents including hydroxyl, amino, cyano, nitro, carboxylic acid and carboxylic acid derivatives, sulfonamide/sulfone-like fragments, ether/thioether-like fragments, and sulfonyl variants).
- R83: limited to H, fluoro, chloro.
- R112: limited to optionally substituted C2-6 alkyl, optionally substituted aryl, optionally substituted heteroaryl, or —NR79R80.
- R68: broad, but with important “no-forbidden-linkage” exclusions when R68 is alkenyl or alkynyl:
- If R68 is optionally substituted lower alkenyl, no alkene carbon is bound to heteroatom-containing moieties or carbonyl/sulfide-type atoms of: —OR68, —SR68, —NR69R68, —C(O)R68, —C(S)R68, —C(O)OR68, —C(O)NR69R68, —C(S)NR69R68, —S(O)2NR69R68, and related C(O)/C(S) and sulfonamide/sulfone patterns.
- The same concept applies when R68 is optionally substituted lower alkynyl, using the “no forbidden bond” rule for alkyne carbon(s).
Interpretive impact: these linkage exclusions reduce accidental “overbreadth” arguments and narrow the set of chemical structures that can be read as Formula III where R68 is unsaturated.
What about compositions, kits, and salts?
US7863288 extends beyond molecules:
- Claim 2: composition = pharmaceutically acceptable carrier + compound of claim 1.
- Claim 3: kit = compound of claim 1 (with any accompanying kit components implied by the kit claim).
- Multiple dependent claims recite “and pharmaceutically acceptable salts thereof.”
Practical consequence: infringement theories can include both drug product forms (if within the composition claim reading) and distribution as part of a kit.
How many claim “coverage lanes” does US7863288 create: genus vs dependent examples?
US7863288 has one independent genus claim with very wide R-group language, then a long dependent tail that functions like a coverage map for likely commercial embodiments.
Genus lane (Claim 1)
- Very broad variable scope, especially R81 and R112.
- Restrains R83 to H/F/Cl.
- Restrains R112 to alkyl/aryl/heteroaryl/NR79R80.
Composition and kit lanes (Claims 2–3)
- Captures drug product and combination packaging, not only the active ingredient.
Narrowing lane (Claims 4–41+)
Dependent claims 4–41 layer additional narrowing:
- Claim 4 limits R81 selection to a subset of the claim-1 list (still broad but excludes some groups).
- Claims 5–10 define how “optionally substituted” operates for lower alkyl/alkenyl/alkynyl and for R68’s substitution patterns, including explicit counts (1–3 substituents on certain substituent groups).
- Claims 11–15 provide example-constrained R81 and R112 selections (including named heterocycles and substituted phenyl fragments).
- Claims 16–54 explicitly list numerous concrete compounds (many with propane/butane sulfonic acid salts and benzamide/sulfonamide frameworks).
- Claims 55+ in your extract end at Claim 54, but the pattern indicates a deep tail of enumerated embodiments.
Coverage insight: for enforcement and freedom-to-operate, the enumerated dependent claims identify a “heat zone” of structures that courts often treat as the intended embodiment. Even when the genus is broad, those dependent examples can anchor construction arguments toward the patent’s chemistry narrative.
What formulations are protected by US7863288 beyond the active ingredient?
US7863288 does not show, in the claim text provided, classic formulation-specific limitations such as:
- polymorph designation,
- particle size,
- controlled-release matrices,
- excipient ratios,
- process parameters,
- or specific dosing regimens.
Instead, the formulation protection is structural and distribution-oriented:
- Composition claim 2 is a generic carrier composition claim.
- Kit claim 3 is distribution packaging oriented.
Practical implication: formulation exclusivity for specific drug product embodiments usually comes from additional patents (process, solid form, formulation/process for the marketed dosage form), not from this composition claim alone.
When does US7863288 lose exclusivity: how to think about expiration mechanics?
No filing, priority date, or patent term data is present in the prompt extract. Without those inputs, an accurate legal expiration date cannot be derived.
Which companies are at risk under US7863288 for infringement?
No product name, listed NDA/BLA, or Orange Book entry is provided in the prompt. Without that linkage, company attribution would be guesswork.
What generic entry risks exist if a generic files against the reference product?
No reference product identity, FDA application number, or Paragraph IV event data is provided in the prompt. Without that, no actionable entry-risk map can be made.
How broad is claim 1 in practice: R81, R83, R112, and the R68 “unsaturation linkage” limits?
R83 limitation (H/F/Cl)
This is a strong narrowing term. If a candidate product places a different substituent on the corresponding position, it may fall outside the claim even if other parts match.
R112 limitation (C2-6 alkyl / aryl / heteroaryl / —NR79R80)
R112 governs the identity of a key substituent. A competitor using:
- larger alkyl than C2–C6,
- constrained ring sizes incompatible with the “optionally substituted C2-6 alkyl” definition,
- or alternative substituent classes (e.g., substituted alkoxy, sulfonamide directly attached if not within the allowed classes)
could avoid claim 1 if the product does not fit the allowed R112 categories.
R68 limitation via linkage exclusions
The R68 restrictions for alkenyl/alkynyl cases are the principal “structural design-around” handle in your provided claim set:
- If a design places heteroatom/carbonyl/sulfone-like binding directly at the alkene/alkyne carbon in a way that corresponds to the prohibited “no bond to” list, it may avoid the claim even while maintaining a similar looking scaffold.
Enforcement observation: genus claims with detailed “bonding exclusions” reduce the risk that trivial peripheral changes accidentally remain infringing; they also increase the burden on infringement analysis to map exact connectivity, not just substituent presence.
What patent estate does US7863288 likely belong to: continuation-style layering and typical follow-on claim types?
The dependent claim structure suggests a chemistry patent aimed at:
- broad structural genus,
- plus numerous explicit embodiment examples across sulfonamide/sulfonate variants and sulfonyl anilide/aryl systems.
In most such estates, additional US patents in the same family often cover:
- selected exemplified compounds with narrower claims,
- specific salt forms and hydrates/solvates,
- polymorphs and solid-state forms,
- crystallization/process claims,
- specific dosage forms (tablets/capsules),
- and, in some cases, method-of-use claims if the composition is tied to a biological target.
Without family identifiers (publication numbers, assignee name, or continuation data), those follow-on layers cannot be enumerated here.
How does US7863288 compare with typical drug patent strategies: genus-first vs embodiment-first?
US7863288’s strategy is genus-first (claim 1) with a deep embodiment list in dependent claims.
Compared with embodiment-first patents:
- Genus-first offers earlier broad coverage and can complicate design-around if the R-group schema is permissive.
- The long dependent list reduces the risk that the genus construction is treated as too abstract by showing concrete intended compounds.
The most likely litigation focal point is therefore claim construction of the Formula III variables (R81/R83/R112/R68) and mapping of the accused compound to the specific substituted patterns and connectivity exclusions.
Key claim-to-embodiment mapping: what the dependent claims reveal about the protected chemical space
Your provided excerpt includes many explicit compounds. They cluster around:
- pyrrolo[2,3-b]pyridine core substituents,
- difluoro substitution at a phenyl ring position (2,4-difluoro is repeated),
- sulfonic acid-derived side chains (propane-1-sulfonic acid, butane-1-sulfonic acid, dimethylamine-1-sulfonic acid, piperidine-1-sulfonic acid, thiophene/benzo[b]thiophene sulfonic acids, and benzene sulfonamide substitutions),
- and aryl/heteroaryl groups attached through carbonyl linkages (named carbonyl positions appear repeatedly, e.g., “pyrrolo[...]pyridine-3-carbonyl” and “pyrrolo[...]pyridine-3-carbonyl”-bearing moieties).
This is the practical “infringement radar” for competitors: if a competitor’s candidate drug uses a pyrrolo[2,3-b]pyridine scaffold with the same core substitution pattern and sulfonyl amide/salt-like functional group types, it is likely inside the dependent-claim heat map, and possibly inside claim 1.
Example embodiment clusters explicitly enumerated (from your excerpt)
- Propane-1-sulfonic acid [2,4-difluoro-3-(...pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide variants with R81-like aryl/heteroaryl substituents on the pyrrolo ring (e.g., 1H-pyrrolo core with substituted positions, methyl/isopropyl/isopropenyl/ethoxy/pyridinyl/pyrrolo-linked substituents).
- Propane-1-sulfonic acid {3-[2,6-difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-carboxylic acids and their methyl/ethyl esters.
- Benzenesulfonamide derivatives with substituted benzene sulfonamides (including trifluoromethyl-benzenesulfonamide motifs).
- Thiophene/benzo[b]thiophene sulfonic acid derivatives and heteroaryl sulfonamides.
Key takeaways
- US7863288’s independent claim 1 is a Formula III genus with broad substitution latitude, but it is constrained by R83 (H/F/Cl), limited R112 classes, and explicit connectivity exclusions when R68 is alkenyl/alkynyl.
- The patent adds carrier-based composition protection and kit distribution protection, but does not, in the provided claim text, specify dosage form technologies, solid-state forms, or process steps.
- The dependent claims enumerate a large number of sulfonamide/sulfonate-containing pyrrolo[2,3-b]pyridine derivatives, signaling the likely intended embodiments and providing a practical claim-construction anchor for infringement analysis.
- Enforceable risk for a competitor hinges on exact substituent identity and attachment patterns for R81/R83/R112 and the forbidden bonding conditions linked to R68’s unsaturation.
FAQs
1) Does US7863288 protect drug salts only, or also free bases?
The independent claim explicitly covers the “compound” and “pharmaceutically acceptable salt thereof,” and dependent claims repeatedly include salt coverage.
2) What is the biggest design-around lever in US7863288?
Changing the substituent identity such that it falls outside the limited categories for R83 and R112, or altering connectivity so that R68 unsaturation violates the “no forbidden bond” constraints.
3) Can a manufacturer avoid infringement by selling a formulation with a different carrier?
Not based on claim 2 alone. The claim uses “pharmaceutically acceptable carrier,” so carrier changes do not, by themselves, remove the carrier element.
4) Do the kit claims require specific co-packaged components?
The kit claim as provided is tied to a kit comprising the claimed compound. Without additional text, the kit claim does not appear to require specific named co-ingredients in your excerpt.
5) Are method-of-use or dosing regimen patents included in the claim set you provided?
Not in the claims shown. The provided claims cover compounds, compositions, and kits, not explicit method-of-use or treatment claims.
References
- United States Patent Application / Patent No. US 7,863,288 (US7863288). Claims provided in prompt text.
